Elsevier

The Lancet

Volume 354, Issue 9173, 10 July 1999, Pages 131-132
The Lancet

Research Letters
Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

https://doi.org/10.1016/S0140-6736(98)04793-XGet rights and content

Summary

We prospectively studied 50 patients treated with interferon-α for chronic hepatitis and found no evidence that patients with a pre-existing mood or anxiety disorder were more likely than other patients to interrupt the interferon-α therapy.

References (5)

  • MH Woo et al.

    Interferon alfa in the treatment of chronic viral hepatitis B and C

    Ann Pharmacother

    (1997)
  • PF Renault et al.

    Psychiatric complications of long-term interferon alpha therapy

    Arch Intern Med

    (1987)
There are more references available in the full text version of this article.

Cited by (164)

  • The risk of new onset depression in association with influenza - A population-based observational study

    2016, Brain, Behavior, and Immunity
    Citation Excerpt :

    Cytokines are part of the cell-to-cell communication in the immune system with pro- or anti-inflammatory properties. Further support of this hypothesis was also provided by clinical observations on patients treated with interferon (IFN) and interleukin-2 (IL-2) who displayed influenza-like symptoms and nonspecific neuropsychiatric symptoms including anorexia, fatigue, altered sleep patterns and pain, with a prevalence ranging from 0% to 45% (Baraldi et al., 2012; Pariante et al., 1999). In most cases, these symptoms could be successfully treated with antidepressants (Khairova et al., 2009).

View all citing articles on Scopus
View full text